QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.105.097931v1 317/2/704    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hsiao, P. Articles by Unadkat, J. D. Search for Related Content PubMed PubMed Citation Articles by Hsiao, P. Articles by Unadkat, J. D.

ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

Verapamil P-glycoprotein Transport across the Rat Blood-Brain Barrier: Cyclosporine, a Concentration Inhibition Analysis, and Comparison with Human Data

Department of Pharmaceutics (P.H., L.S., J.D.U.), Division of Nuclear Medicine (J.M.L., D.A.M., M.M.), and Department of Medicine (A.C.C.), University of Washington, Seattle, Washington

To predict the magnitude of P-glycoprotein (P-gp)-based drug interactions at the human blood-brain barrier (BBB), rodent studies are routinely conducted where P-gp is chemically inhibited. For such studies to be predictive of interactions at the human BBB, the plasma concentration of the P-gp inhibitor must be comparable with that observed in the clinic. Therefore, we determined the in vivo EC₅₀ of P-gp inhibition at the rat BBB using verapamil as a model P-gp substrate and cyclosporine A (CsA) as the model P-gp inhibitor. Under isoflurane anesthesia, male Sprague-Dawley rats were administered i.v. CsA to achieve pseudo steady-state CsA blood concentrations ranging from 0 to 12 µM. Then, an i.v. tracer dose of [³H]verapamil was administered, and 20 min after verapamil administration, the animals were sacrificed for determination of blood, plasma, and brain ³H radioactivity by scintillation counting. The percentage increase in the brain/blood ³H radioactivity (relative to 0 µM CsA) was described by the Hill equation with E_max, 1290%; EC₅₀, 7.2 µM; and , 3.8. Previously, using [¹¹C]verapamil, we have shown that the human brain/blood ¹¹C radioactivity was increased by 79% at 2.8 µM CsA blood concentration. At an equivalent CsA blood concentration, the rat brain/blood ³H radioactivity was increased by a remarkably similar extent of 75%. This is the first time that an in vivo CsA EC₅₀ of P-gp inhibition at the rat BBB has been determined and the magnitude of such inhibition was compared between the rat and the human BBB at the same blood CsA concentration.

Address correspondence to: Dr. Jashvant (Jash) Unadkat, School of Pharmacy, Department of Pharmaceutics, University of Washington, Box 357610, Seattle, WA 98195. E-mail: jash{at}u.washington.edu

This article has been cited by other articles:

				S. Eyal, F. S. Chung, M. Muzi, J. M. Link, D. A. Mankoff, A. Kaddoumi, F. O'Sullivan, M. F. Hebert, and J. D. Unadkat Simultaneous PET Imaging of P-Glycoprotein Inhibition in Multiple Tissues in the Pregnant Nonhuman Primate J. Nucl. Med., May 1, 2009; 50(5): 798 - 806. [Abstract] [Full Text] [PDF]

				S. Syvanen, O. Lindhe, M. Palner, B. R. Kornum, O. Rahman, B. Langstrom, G. M. Knudsen, and M. Hammarlund-Udenaes Species Differences in Blood-Brain Barrier Transport of Three Positron Emission Tomography Radioligands with Emphasis on P-Glycoprotein Transport Drug Metab. Dispos., March 1, 2009; 37(3): 635 - 643. [Abstract] [Full Text] [PDF]

				N. Lloberas, J. Torras, G. Alperovich, J. M. Cruzado, P. Gimenez-Bonafe, I. Herrero-Fresneda, M.{m. d.}l. Franquesa, I. Rama, and J. M. Grinyo Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats Nephrol. Dial. Transplant., October 1, 2008; 23(10): 3111 - 3119. [Abstract] [Full Text] [PDF]

				J. P. Bankstahl, C. Kuntner, A. Abrahim, R. Karch, J. Stanek, T. Wanek, W. Wadsak, K. Kletter, M. Muller, W. Loscher, et al. Tariquidar-Induced P-Glycoprotein Inhibition at the Rat Blood-Brain Barrier Studied with (R)-11C-Verapamil and PET J. Nucl. Med., August 1, 2008; 49(8): 1328 - 1335. [Abstract] [Full Text] [PDF]

				X. Liu, C. Chen, and B. J. Smith Progress in Brain Penetration Evaluation in Drug Discovery and Development J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 349 - 356. [Abstract] [Full Text] [PDF]

				B. Elbaz, A. Alperovitch, M. M. Gottesman, C. Kimchi-Sarfaty, and H. Rahamimoff Modulation of Na+-Ca2+ Exchanger Expression by Immunosuppressive Drugs Is Isoform-Specific Mol. Pharmacol., April 1, 2008; 73(4): 1254 - 1263. [Abstract] [Full Text] [PDF]

				P. Hsiao, T. Bui, R. J. Y. Ho, and J. D. Unadkat In Vitro-to-in Vivo Prediction of P-glycoprotein-Based Drug Interactions at the Human and Rodent Blood-Brain Barrier Drug Metab. Dispos., March 1, 2008; 36(3): 481 - 484. [Abstract] [Full Text] [PDF]

				A. Takano, H. Kusuhara, T. Suhara, I. Ieiri, T. Morimoto, Y.-J. Lee, J. Maeda, Y. Ikoma, H. Ito, K. Suzuki, et al. Evaluation of In Vivo P-Glycoprotein Function at the Blood-Brain Barrier Among MDR1 Gene Polymorphisms by Using 11C-Verapamil J. Nucl. Med., September 1, 2006; 47(9): 1427 - 1433. [Abstract] [Full Text] [PDF]